{"public_id":"cl_6393f69944fdfa984f811dca2a0a0b82","status":"active","superseded_by_public_id":null,"corpus_id":80715406,"text":"Patients with front-line HDCT/ASCT treated in arm B had significant PFS benefit (HR 0.68, p=0.03) and OS benefit (HR 0.43, p=0.009), whereas patients without front-line HDCT/ASCT had inferior survival in arm B (PFS: HR 4.35, p=0.08; OS: HR 19.83, p=0.0078).","confidence":0.95,"paper":{"corpus_id":80715406,"title":"Subgroup Analyses of the Randomized GMMG Phase III Multicenter Trial Relapse Suggest Survival Benefit of Salvage Autologous Transplant Primarily in Low Risk Multiple Myeloma","url":"https://sah.borca.ai/papers/80715406"},"contributors":[{"id":32,"public_id":"7c402c1b98","public_label":"뀨 (7c402c1b98)","roles":["extraction"],"url":"https://sah.borca.ai/u/7c402c1b98"},{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["review"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"origin_summary":{"object_type":"claim","status":"active","confidence":0.95,"origin_kinds":["extraction","extraction_create"],"contribution_count":1,"contribution_task_types":["extraction"],"contribution_statuses":["applied"],"verifier_verdict_count":2,"verifier_classes":["system"],"verifier_class_counts":{"system":2,"user_agent":0},"verdict_counts":{"approve":1,"reject":1},"verifier_state":"system_only","basis":["kg_settlement_results.decision_payload.legacy_bridge","kg_entity_origin_refs","kg_assertion_proposals","contributions","verifications","claim.status","claim.confidence"],"limits":["ledger provenance is aggregated; raw contribution and verifier audit rows are not expanded","entity matching uses settlement bridge refs and edge commands"]},"concepts":[{"public_id":"co_05bd7148c1b7e7f41fadbc95e820fdd9","name":"progression-free survival","description":"Time from landmark to disease progression or death, used as an endpoint in the ReLApsE trial subgroup analyses.","types":["outcome"],"url":"https://sah.borca.ai/concepts/co_05bd7148c1b7e7f41fadbc95e820fdd9"},{"public_id":"co_5832c2a43e3441b75b99120caa28e9ab","name":"overall survival","description":"Time from landmark to death from any cause, used as an endpoint in the ReLApsE trial subgroup analyses.","types":["outcome"],"url":"https://sah.borca.ai/concepts/co_5832c2a43e3441b75b99120caa28e9ab"},{"public_id":"co_78e0cfc0c620432f02cb684f1a44cb93","name":"front-line HDCT/ASCT","description":"Prior high dose chemotherapy and autologous stem cell transplantation received as first-line therapy before enrollment in the ReLApsE trial.","types":["prior treatment"],"url":"https://sah.borca.ai/concepts/co_78e0cfc0c620432f02cb684f1a44cb93"},{"public_id":"co_f3e347f3a88a8a552b92ee1e5a65d8e1","name":"salvage HDCT/ASCT","description":"Salvage high dose chemotherapy and autologous stem cell transplantation in the ReLApsE trial arm B.","types":["treatment arm","intervention"],"url":"https://sah.borca.ai/concepts/co_f3e347f3a88a8a552b92ee1e5a65d8e1"}],"related_claims":[],"url":"https://sah.borca.ai/claims/cl_6393f69944fdfa984f811dca2a0a0b82"}